17 January 2007 Cambridge, UK and Cambridge, Massachusetts – 17 January 2007 – Acambis plc (Acambis) (LSE: ACM) announces that it has received a Complete Response Letter from the US Food and Drug Administration (FDA) in response to its Biologics Licence Application (BLA) for its ACAM2000 smallpox vaccine. The response is part of the normal review process by the FDA and the letter was received ahead of the First Action Due Date of 14 February 2007.
